Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

A Phase II Study of Proton-Based Radiation Therapy With Elective Pelvic Nodal Irradiation, Concomitant Docetaxel, and Adjuvant Androgen Deprivation for High-Risk Prostate Adenocarcinoma

The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.

Inclusion Criteria:

* Adenocarcinoma of the prostate.

Exclusion Criteria:

• Previous prostate cancer treatment such as chemotherapy and/or pelvic radiation.
• Active inflammatory bowel disease (diverticulitis, Crohn's disease or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed.)
• History of hip replacement.
• Prior intrapelvic surgery. This includes the following:
• Transrectal or rectal surgery other than polypectomy or hemorrhoid removal or banding
• Transabdominal pelvic surgery
• Bladder surgery
• Prior myocardial infarction (MI) or congestive heart failure (CHF).
• Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.